Swedish Orphan Biovitrum AB (publ) (SOBI.ST)
SEK 310.4
(-0.06%)
SEK 310.4
(-0.06%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 9.39 Billion SEK | -7.59% |
| 2022 | 10.16 Billion SEK | 23.14% |
| 2021 | 8.25 Billion SEK | 9.05% |
| 2020 | 7.57 Billion SEK | 18.07% |
| 2019 | 6.41 Billion SEK | 78.21% |
| 2018 | 3.59 Billion SEK | 19.76% |
| 2017 | 3 Billion SEK | 17.63% |
| 2016 | 2.55 Billion SEK | 37.28% |
| 2015 | 1.86 Billion SEK | 21.36% |
| 2014 | 1.53 Billion SEK | 12.87% |
| 2013 | 1.35 Billion SEK | -0.09% |
| 2012 | 1.35 Billion SEK | 16.92% |
| 2011 | 1.16 Billion SEK | 1.71% |
| 2010 | 1.14 Billion SEK | 20.58% |
| 2009 | 948.32 Million SEK | 7983.2% |
| 2008 | 11.73 Million SEK | -98.62% |
| 2007 | 850.48 Million SEK | 5.94% |
| 2006 | 802.81 Million SEK | 104.08% |
| 2005 | 393.38 Million SEK | 15.86% |
| 2004 | 339.53 Million SEK | -65.55% |
| 2003 | 985.56 Million SEK | 49.17% |
| 2002 | 660.7 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 3.39 Billion SEK | 18.84% |
| 2024 Q2 | 2.65 Billion SEK | -21.83% |
| 2024 Q3 | 3.52 Billion SEK | 32.83% |
| 2023 Q2 | 3.08 Billion SEK | 15.24% |
| 2023 Q4 | 2.85 Billion SEK | -17.29% |
| 2023 Q3 | 3.45 Billion SEK | 11.89% |
| 2023 Q1 | 2.67 Billion SEK | -2.08% |
| 2023 FY | 9.39 Billion SEK | -7.59% |
| 2022 Q3 | 2.36 Billion SEK | -2.67% |
| 2022 Q4 | 2.73 Billion SEK | 15.5% |
| 2022 Q2 | 2.43 Billion SEK | -7.6% |
| 2022 FY | 10.16 Billion SEK | 23.14% |
| 2022 Q1 | 2.63 Billion SEK | 14.43% |
| 2021 Q1 | 1.9 Billion SEK | -2.86% |
| 2021 Q4 | 2.3 Billion SEK | 9.89% |
| 2021 Q3 | 2.09 Billion SEK | 6.78% |
| 2021 Q2 | 1.96 Billion SEK | 3.1% |
| 2021 FY | 8.25 Billion SEK | 9.05% |
| 2020 Q3 | 1.87 Billion SEK | 1.85% |
| 2020 Q1 | 1.9 Billion SEK | -4.67% |
| 2020 Q2 | 1.84 Billion SEK | -3.11% |
| 2020 FY | 7.57 Billion SEK | 18.07% |
| 2020 Q4 | 1.95 Billion SEK | 4.43% |
| 2019 Q3 | 1.42 Billion SEK | -18.16% |
| 2019 Q4 | 1.99 Billion SEK | 40.35% |
| 2019 FY | 6.41 Billion SEK | 78.21% |
| 2019 Q1 | 1.26 Billion SEK | 16.34% |
| 2019 Q2 | 1.73 Billion SEK | 36.94% |
| 2018 FY | 3.59 Billion SEK | 19.76% |
| 2018 Q3 | 921 Million SEK | 10.17% |
| 2018 Q2 | 836 Million SEK | 11.17% |
| 2018 Q4 | 1.08 Billion SEK | 18.24% |
| 2018 Q1 | 752 Million SEK | -3.24% |
| 2017 FY | 3 Billion SEK | 17.63% |
| 2017 Q4 | 777.2 Million SEK | 10.56% |
| 2017 Q3 | 703 Million SEK | -10.1% |
| 2017 Q2 | 782 Million SEK | 5.25% |
| 2017 Q1 | 743 Million SEK | -6.74% |
| 2016 FY | 2.55 Billion SEK | 37.28% |
| 2016 Q3 | 611 Million SEK | -0.16% |
| 2016 Q1 | 534 Million SEK | 6.16% |
| 2016 Q2 | 612 Million SEK | 14.61% |
| 2016 Q4 | 796.72 Million SEK | 30.4% |
| 2015 Q3 | 461 Million SEK | -3.96% |
| 2015 FY | 1.86 Billion SEK | 21.36% |
| 2015 Q1 | 417 Million SEK | 247.68% |
| 2015 Q4 | 502.99 Million SEK | 9.11% |
| 2015 Q2 | 480 Million SEK | 15.11% |
| 2014 Q4 | 119.93 Million SEK | -65.3% |
| 2014 FY | 1.53 Billion SEK | 12.87% |
| 2014 Q3 | 345.6 Million SEK | -11.43% |
| 2014 Q2 | 390.2 Million SEK | -42.42% |
| 2014 Q1 | 677.7 Million SEK | 82.56% |
| 2013 Q2 | 348.6 Million SEK | 13.81% |
| 2013 Q1 | 306.3 Million SEK | -32.39% |
| 2013 Q4 | 371.21 Million SEK | 11.64% |
| 2013 FY | 1.35 Billion SEK | -0.09% |
| 2013 Q3 | 332.5 Million SEK | -4.62% |
| 2012 Q3 | 291.6 Million SEK | -7.93% |
| 2012 Q4 | 453.05 Million SEK | 55.37% |
| 2012 FY | 1.35 Billion SEK | 16.92% |
| 2012 Q1 | -17.1 Million SEK | -104.53% |
| 2012 Q2 | 316.7 Million SEK | 1952.05% |
| 2011 Q2 | 149.2 Million SEK | -57.08% |
| 2011 Q3 | 288.4 Million SEK | 93.3% |
| 2011 FY | 1.16 Billion SEK | 1.71% |
| 2011 Q4 | 377.8 Million SEK | 31.0% |
| 2011 Q1 | 347.6 Million SEK | 33.85% |
| 2010 FY | 1.14 Billion SEK | 20.58% |
| 2010 Q1 | 309.5 Million SEK | 25.39% |
| 2010 Q2 | 300.4 Million SEK | -2.94% |
| 2010 Q4 | 259.7 Million SEK | -5.18% |
| 2010 Q3 | 273.9 Million SEK | -8.82% |
| 2009 Q3 | 217.3 Million SEK | -14.35% |
| 2009 Q1 | 230.5 Million SEK | 0.0% |
| 2009 Q4 | 246.82 Million SEK | 13.59% |
| 2009 FY | 948.32 Million SEK | 7983.2% |
| 2009 Q2 | 253.7 Million SEK | 10.07% |
| 2008 FY | 11.73 Million SEK | -98.62% |
| 2007 FY | 850.48 Million SEK | 5.94% |
| 2006 FY | 802.81 Million SEK | 104.08% |
| 2005 FY | 393.38 Million SEK | 15.86% |
| 2004 FY | 339.53 Million SEK | -65.55% |
| 2003 FY | 985.56 Million SEK | 49.17% |
| 2002 FY | 660.7 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AcuCort AB | 13.24 Million SEK | -70826.108% |
| AlzeCure Pharma AB (publ) | 38.26 Million SEK | -24459.615% |
| BioGaia AB (publ) | 507.08 Million SEK | -1753.137% |
| Enzymatica AB (publ) | 79.92 Million SEK | -11657.272% |
| Enorama Pharma AB (publ) | 38.22 Million SEK | -24482.745% |
| Gabather AB (publ) | 9.47 Million SEK | -99087.249% |
| Klaria Pharma Holding AB (publ.) | 14.88 Million SEK | -63034.91% |
| Moberg Pharma AB (publ) | 27.46 Million SEK | -34116.946% |
| Nanexa AB (publ) | 135.78 Million SEK | -6820.652% |
| Newbury Pharmaceuticals AB (publ) | 30.11 Million SEK | -31107.864% |
| ODI Pharma AB | -5.00 SEK | 187940000100.0% |
| Orexo AB (publ) | 659.4 Million SEK | -1325.083% |
| Probi AB (publ) | 208.93 Million SEK | -4397.614% |
| Swedencare AB (publ) | 1.12 Billion SEK | -733.215% |
| Toleranzia AB | 6.97 Million SEK | -134681.985% |
| Vivesto AB | 355.71 Million SEK | -2541.699% |